Economic Impact of Gene Editing Technology: The Contribution of Personalized Medicine, Bioinformatics, and Artificial Intelligence

Ruiyi Shen [1,#], Xinyi Shen [2,#] and Peishi Wu [3,*]

[1] Shenzhen Vanke Meisha Academy, Shenzhen 518000, Guangdong, China
[2] Rutgers University, New Brunswick, NJ 08901, United States
[3] School of Environment and Energy, Shenzhen Graduate School of Peking University, Shenzhen 518000, China
[#] These authors contributed equally to this work.
[*] Corresponding author: Peishi Wu

Abstract: The present investigation explores the profound economic ramifications of gene editing technologies, especially CRISPR/Cas9, ZFNs, and TALENs, underscoring their significant contributions within the domains of personalized medicine, bioinformatics, and artificial intelligence. Employing a comprehensive literature review, this study integrates and analyzes copious related scholarly sources, unveiling the specific applications of these technologies in the mentioned sectors, and providing an in-depth discussion concerning their economic implications. The findings indicate that these gene editing techniques have exerted a profound influence within the realms of bioinformatics, artificial intelligence, and personalized medicine, initiating transformations in medical models and engendering considerable economic benefits. The pivotal roles of gene sequencing and gene therapy in personalized medicine, along with their impacts on bioinformatics and artificial intelligence, receive detailed elucidation. However, a margin of error may exist in the global evaluation of the practical applications and economic effects of gene editing technologies, indicating that their potential impacts may not yet be fully exposed. Future investigations will delve further into the utilization of gene editing technologies in other sectors such as environmental conservation and land use, their impacts on the global economy and society, and the in-depth study of bioinformatics and artificial intelligence in gene editing. Overall, this investigation not only furnishes compelling evidence for understanding the profound economic impacts of gene editing technologies but also offers new perspectives for future research and provides important tools and strategies for propelling biotechnological advancement and sustainable socio-economic growth.

Keywords: gene editing technology; personalized medicine; bioinformatics; artificial intelligence; economic impact; iterature review

1. Introduction

With the rapid advancement of biotechnology, gene editing techniques such as CRISPR/Cas9, ZFNs, and TALENs have emerged as critical underpinnings in personalized medicine, bioinformatics, and artificial intelligence domains. These gene-editing techniques have elicited widespread interest in the global scientific community, owing to their enormous potential and broad applicability. Particularly, the discovery of homologous recombination has rendered precise DNA-level editing feasible, while the swift development of CRISPR-Cas9, with its simplicity, precision, and cost-effectiveness, provides a robust instrument for biological research [1, 2]. They exhibit immense potential for applications in the treatment and prevention of genetic diseases [3-5]. Nevertheless, numerous challenges necessitate addressing, including optimizing therapeutic strategies, deepening understanding of disease mechanisms, identifying novel therapeutic targets, developing safe and effective gene-editing plans, and integrating bioinformatics and artificial intelligence into gene editing to enhance efficiency and precision [5].

The economic contribution of gene editing primarily derives from its widespread applications across various sectors. In the medical field, the roles of specific genes in stem cell differentiation and pluripotency have been revealed, thus propelling advancements in stem cell-based therapeutic methods, and demonstrating potential for treating blood, heart, and kidney diseases [6-8]. In agriculture, advancements in gene-editing technology could dramatically transform the future of crop improvement and sustainable farming [9]. Specifically, the application of CRISPR-Cas9 in crop genomics has expedited the creation of animal models, making a significant contribution to agricultural research [10]. Concurrently, livestock gene-editing techniques could potentially control future epidemics and improve animal health. In agriculture, gene-editing techniques play a pivotal role in ensuring food safety and reducing economic losses for farmers, achieved through enhancing crop yields, improving nutritional components, and bolstering resistance to pests, diseases, and environmental stressors [11, 12]. In medicine, gene editing heralds a new era of targeted therapies, personalized medicine, and gene-based diagnostics, providing novel avenues for medical research and development, beneficial to both patients and healthcare systems [13].

Understanding the economic ramifications of gene-editing technologies, particularly their contributions to personalized medicine, bioinformatics, and artificial intelligence, is of profound significance across diverse domains, such as healthcare, biotechnology, intellectual property rights, regulatory norms, agriculture, environmental and land use [14-21]. Explorations in this realm can help bridge knowledge gaps in these sectors while delineating novel avenues for future research. The impact of gene-editing technologies is not confined to medical and agricultural sectors but extends widely into the biotechnology industry. The simplicity, efficiency, and cost-effectiveness of gene editing have secured its pivotal role in the production of biological drugs, the creation of transgenic organisms and cell lines, and studies of genomic structure and function. Such applications catalyze the development of innovative products and processes, driving economic growth and generating fresh market opportunities [22]. Moreover, gene-editing technologies display unparalleled potential in addressing global challenges, such as reducing the use of harmful pesticides, improving nutritional efficiency, and enhancing crop resistance to climate-related stressors, thereby contributing to sustainable agriculture [23]. However, the widespread application and development of gene-editing technologies necessitate considerations of factors such as public acceptance, technological access, and policy regulations. Establishing and reforming regulatory frameworks, enhancing public awareness and acceptance of gene-editing technologies, and ensuring equitable access to these technologies are key determinants of their economic benefits [24].

This research aims to elucidate how gene editing technology contributes to economic augmentation, and how personalized medicine, bioinformatics, and artificial intelligence utilize these technologies to stimulate economic growth. Additionally, the investigation intends to assess the role these technologies play in optimizing the development and implementation of biotechnologies and their economic ramifications. To fulfil these objectives, the study will adopt a literature review approach, extracting information about gene editing technology, bioinformatics, artificial intelligence, and their economic impacts from a plethora of publications, and offering comprehensive analysis and discussion on these technologies' applications in personalized medicine, bioinformatics, and artificial intelligence, and their influence on the economy.

The ensuing content of the paper will first offer a thorough overview of gene editing technology and its applications in personalized medicine and biotechnology. Subsequently, a detailed analysis of the economic impact engendered by gene editing technology will be provided, inclusive of market opportunities, intellectual property implications, and regulatory constraints. Following this, the application of bioinformatics and artificial intelligence in gene editing and personalized medicine, and their impact on the economy, will be discussed. Finally, a summarization of salient findings will be presented, with elucidation of limitations encountered during the research and recommendations for prospective studies.

2. Gene Editing Technology and Its Economic Implications

2.1. Comprehensive Overview of Gene Editing Technology

Gene editing technology, a pivotal instrument in contemporary biotechnology, profoundly influences bioinformatics, artificial intelligence, and personalized medicine. Such technology predominantly employs methods inclusive of gene editing, CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), and Transcription Activator-Like Effector Nucleases (TALENs) to enact precise C-to-T transformations in specific genes, thereby facilitating targeted point mutations [3, 4]. The simplicity, efficiency, and versatility of the CRISPR/Cas9 system render it the most widely utilized gene editing technique, using guide RNA to direct the Cas9 protein to specific genomic locations, thus achieving precise gene modifications [4]. While the early ZFNs and TALENs technologies present certain advantages, the dominance of CRISPR/Cas9 in biological research prevails due to their complexity and limitations. The advancement of personalized medicine, bioinformatics, and AI spurs the progress of gene editing technology. Personalized medicine applies gene editing technology to devise treatment plans based on individual genetic characteristics. Bioinformatics and AI furnish formidable tools for genomic data analysis, guide RNA design, off-target effect prediction, as well as the prediction of targeting efficiency and specificity of CRISPR/Cas9. Such integrated technologies bear immense potential for the advancement of gene and cell therapies, the development of targeted therapies, and the prevention and treatment of diseases, exerting far-reaching impacts on the global economy. In summation, gene editing technology has demonstrated substantial advantages in providing personalized medical treatment, optimizing treatment strategies, understanding disease mechanisms, identifying novel therapeutic targets, and facilitating the development of safe, effective gene editing schemes. This progress propels the advancement in biomedicine, bioinformatics, and AI, accelerating the translation towards clinical applications.

2.2. Applications of Gene Editing Technology in the Medical and Biotechnological Sectors

Gene editing technologies have had profound implications in diverse spheres of medicine and biotechnology, transforming approaches to treatment strategies, pharmaceutical development, disease detection and diagnosis, as well as regenerative medicine, further stimulating innovation in biomaterials. By leveraging CRISPR/Cas9 to rectify disease-related gene mutations, novel pathways have been paved for precision medicine [25]. The technology has augmented pharmaceutical research by facilitating the generation of disease models and providing novel tools for therapeutic target identification [25]. In alliance with bioinformatics and microfluidic systems, gene editing technology has introduced innovative solutions to challenges in disease detection and diagnosis [26]. In the realm of regenerative medicine, gene editing has been deployed to enhance tissue regeneration and forge new methodologies in organ and tissue engineering [27]. In summary, the wide-ranging applications of gene editing in medicine and biotechnology, in conjunction with bioinformatics and microfluidics, are poised to impart far-reaching influences on the medical and biotechnological industries and are anticipated to stimulate economic growth and societal benefits.

2.3. Economic Impact Induced by Gene Editing Technology

The economic repercussions of gene editing technologies pervade globally, interfacing with numerous sectors including medicine, biotechnology, intellectual property, regulation, agriculture, environment, and land use. Innovations in the medical and biotechnological industry, such as CRISPR/Cas9, introduce novel market opportunities, fostering economic growth and instigating entrepreneurial ventures within the biotechnological sphere [14]. Additionally, patents and licensing agreements serve as crucial instruments during the commercialisation process of gene editing technologies, safeguarding inventions and incentivising innovation [14]. In regulatory terms, supportive scientific frameworks foster the development of gene editing technologies. Nevertheless, stringent regulatory environments or public apprehensions could obstruct product commercialisation [15]. Within the agricultural domain, gene editing technologies bolster crop productivity, nutritional content, and resistance, although regulatory policies concerning genetically edited crops could potentially curtail their progression [15]. The applications of gene editing technologies will also impinge on global conservation and land use, potentially affecting insects, land utilisation, and biodiversity [16]. In sum, the economic impacts of gene editing technologies are profound and diverse, creating market opportunities, influencing intellectual property rights, and are concurrently constrained by the regulatory environment, and its effects on agriculture, the environment, and society. Understanding and effectively addressing these impacts is paramount for the successful implementation of gene editing technologies.

3. Personalized Medicine and Its Economic Implications

3.1. Applications of Genomic Sequencing and Gene Therapy in Personalized Medicine

In the domain of healthcare, genetic sequencing and gene therapies are pioneering the advancements in personalized treatment and medical care, affecting economic significance. Genetic sequencing, such as next-generation sequencing techniques, plays a critical role in unveiling genetic mutations, biomarkers, and disease-associated genes, thereby offering indispensable insights into personalized treatment strategies [28]. It is instrumental in understanding the genetic and environmental factors influencing drug responses and disease pathophysiology [28] and has propelled the development of genomic databases and resources [28]. Furthermore, gene therapy, by amending genetic deficiencies or regulating gene expression, is perceived as a promising method for personalized medicine [29]. It has applications in various diseases including cancer, regenerative medicine, and bone disorders, possessing potential for developing individual-specific treatment methods [29]. The evolution of personalized medical strategies also relies on the utilization of various methods such as artificial intelligence, multi-omics analysis, chemoproteomics, and computer-aided drug design [30]. These strategies employ genetic sequencing data and other molecular information to tailor treatments for each patient, aiming to optimize treatment outcomes, minimize adverse reactions, and improve patient care [30]. The advancements in genomic research have a substantial impact on personalized prevention and medical care. Discoveries in genomics, combined with intervention strategies, can provide information to predict an individual's health trajectory, thus revolutionizing healthcare [31]. Nevertheless, the implementation of personalized medicine necessitates overcoming a series of challenges, from gene discovery to translation into interventions and integration into the healthcare system [31]. To fully exploit the potential of genetic sequencing and gene therapies, numerous economic, technological, social, and ethical issues need resolution. In summation, the application of genetic sequencing and gene therapies contributes to optimizing disease treatment effectiveness, improving healthcare services, optimizing the allocation of medical resources, and generating positive economic effects. However, it also necessitates surmounting a series of challenges, providing new directions for future research.

3.2. Economic Benefit Analysis of Personalized Medicine

In the realm of healthcare, the application of personalized treatments, particularly the execution of genomic sequencing and gene therapy, brings forth substantial economic benefits. These technological advancements augment therapeutic efficacy, identify disease-related genes, elevate precision in diagnosis and treatment, reduce medical costs, and enhance patient satisfaction [32-34]. Gene therapy, catering to individual genetic characteristics, anticipates a decline in the necessity for long-term costly interventions, further mitigating healthcare expenses. Personalized healthcare based on genomics yields more precise services, fostering effective resource allocation and cost-benefit analysis, thereby heightening overall healthcare system efficiency [32-34]. These technologies also catalyse innovation and economic growth within the medical and biotechnology sectors [34]. By forestalling diseases, these technologies are expected to alleviate the strain on the healthcare system, distribute medical resources efficiently, and decrease the overall burden and cost of healthcare. In summary, the application of genomic sequencing and gene therapy in personalized healthcare facilitates the enhancement of treatment outcomes, the realization of individualized treatment, cost savings, promotion of economic growth, and relief of healthcare stress, and makes a significant contribution to achieving an efficient, cost-effective healthcare system.

3.3. Anticipations about Medical Outcomes

In the examination of the economic implications of personalized medicine, patients' anticipations about medical outcomes hold a pivotal position. These expectations shape patients' perceptions of treatment efficacy, side effects, and the therapeutic experience [35]. Shaped by personal beliefs, prior experiences, and professional medical information, these expectations directly influence treatment outcomes. Consequently, the comprehension and management of patient expectations serve as an essential method for optimizing treatment results. For instance, negative expectations, also known as nocebos, may lead patients to focus excessively on potential side effects [36], and resolving patients' concerns about side effects is particularly crucial. Moreover, Concealed Stigmatized Identities (CSIs) such as specific medical conditions, can also have psychological, physical, and behavioural effects on individuals [37]. Therefore, managing expectations and addressing the impact of CSIs is critical for improving well-being and reducing negative outcomes. The management of expectations can influence patient adherence to treatment and perceptions of side effects [38], so optimizing treatment expectations in this context can minimize the burden of side effects and enhance the quality of life during treatment. For instance, optimizing expectations through psychological interventions can have a positive impact on the outcomes of breast cancer endocrine treatments [39]. Overall, patients' expectations play a significant role in personalized medicine, and their management and understanding have a decisive impact on improving treatment outcomes, minimizing the burden of side effects, and enhancing patient experience.

4. The Role of Bioinformatics and Artificial Intelligence in Economic Impact

4.1. Applications of Bioinformatics and Artificial Intelligence in Gene Editing and Personalized Medicine

The economic implications of gene-editing technology transcend immediate medical applications, prominently reflected in its stimulation of bioinformatics and Artificial Intelligence (AI). The advancement of these domains has profoundly impacted the gene-editing sphere, presaging a future characterized by enhanced efficiency and precision. Bioinformatics plays a pivotal role in personalized medicine by deciphering voluminous genomic data to identify genetic variations and predict disease risks [24]. Its tools and algorithms have demonstrated considerable value in guide RNA design, off-target effect prediction, and gene expression pattern analysis [5]. However, for complex problems, bioinformatics alone is insufficient, necessitating the introduction of AI to provide novel possibilities for gene editing. AI algorithms enhance the efficiency and precision of gene-editing technologies [5], while machine learning can predict the efficiency and specificity of CRISPR/Cas9 targeting, optimize guide RNA design, and minimize off-target effects. Importantly, AI can analyze complex genomic data to identify disease-related genetic variations and forecast treatment outcomes [17]. In personalized medicine, the application of gene-editing technologies like CRISPR/Cas9 corroborates the value of integrating bioinformatics and AI. They can rectify gene mutations causing disease, develop targeted therapies, and customize treatment plans [24]. This not only highlights the central role of bioinformatics and AI in gene editing and personalized medicine but also brings tangible economic benefits to the bioeconomy. Moreover, they hold substantial value in pharmacogenomics and drug response prediction. By analysing the impact of genetic variations on drug metabolism and efficacy, personalized treatment strategies can be realized. AI can forecast drug reactions, optimize dosages, and reduce adverse reactions [40]. In conclusion, the application of bioinformatics and AI in gene editing and personalized medicine has significant economic repercussions.

4.2. Optimization of Biotechnological Development and Implementation

The rapid evolution of bioinformatics and AI propels economic growth and sustainable development in biotechnology, contributing to the establishment of novel economic models, knowledge management systems, and strategies to enhance biotechnological firms' economic performance [18, 19]. For example, these technologies have found applications in microfluidic tools for optimizing biological processes, cell screening, catalyst encapsulation, and kinetic parameter determination [41]. Bioinformatics and AI are similarly employed to evaluate the potential and constraints of biotechnology in various sectors, such as cassava production and agricultural improvement [42]. These assessments furnish effective methodologies for discerning challenges and opportunities. These advancements will leave a lasting impact on the economy. In the realm of agricultural biotechnology, they have played a pivotal role in crop improvement and quality enhancement, which will bring about substantial economic benefits for the agricultural industry [20]. In conclusion, bioinformatics and AI are of paramount importance in optimizing the development and application of biotechnologies, playing a pivotal role in both fundamental research and economic applications. However, despite the colossal opportunities these technologies bring, challenges cannot be overlooked. Future research should delve deeper into more applications of bioinformatics and AI in biotechnology while staying alert to potential risks and challenges to achieve sustainable development in the field of biotechnology.

4.3. The Economic Impact of Bioinformatics and Artificial Intelligence

The pivotal role of bioinformatics and artificial intelligence (AI) within the realm of biotechnology manifests primarily through five dimensions: cost-saving measures, work efficiency augmentation, research and development acceleration, optimization of data-driven decision-making, and innovation propulsion. Foremost, these technologies have ushered in substantial cost reductions across various sectors. Bioinformatics streamlines workflows, and mitigates procedural complexity [43], while AI substantially accelerates specimen identification in processes such as drug discovery, and optimizes conventional protocols [44]. Concurrently, these technologies enhance work efficiency and productivity—AI's automation capabilities decrease manual labour and elevate output [5]. Additionally, bioinformatics and AI expedite biotechnology research and development. The utilization of AI algorithms allows for quicker insights from biological data, optimizing therapeutic strategies, and accelerating commercialization and market entry, thereby stimulating economic growth [21]. Ultimately, the amalgamation of bioinformatics and AI propels innovation within the biotechnology sector, enhancing the competitive standing of associated enterprises and research institutions [44]. In summation, the application of bioinformatics and AI has driven the evolution of the biotechnology sector, promoting sustainable socio-economic growth, while proffering potent tools and strategies to researchers and decision-makers.

5. Conclusion

The present study has comprehensively encapsulated the progression of precision gene-editing techniques such as CRISPR/Cas9, ZFNs, and TALENs. These technologies have imparted profound influences across disciplines like bioinformatics, artificial intelligence, and personalized medicine, initiating significant transitions in healthcare practices and eliciting substantial economic implications. A novel perspective on the economic ramifications of gene-editing technology has been offered, foretelling the potential profound effects on various sectors including medicine, biotechnology, intellectual property, agriculture, environmental conservation, and land utilization. The role of gene sequencing and gene therapy in personalized medicine and their impacts on bioinformatics and artificial intelligence have also been elucidated.

Despite these critical revelations, it must be acknowledged that the exploration of the potential impacts of gene-editing technology in this research may not be exhaustive. Discrepancies may exist in the evaluation of global practical applications and economic effects of this technology. Future inquiries should delve further into the utilization of gene-editing technology in other areas such as environmental preservation and land use, and its impacts on the global economy and society. Further, an in-depth investigation into the application of bioinformatics and artificial intelligence in gene editing is recommended, with the expectation to discover additional applications in areas like optimization of biological processes, cell screening, catalyst packaging, and determination of kinetic parameters.

In summation, this research provides compelling evidence of the far-reaching economic impacts of gene-editing technology, paving a new path for future investigations. The amalgamation of bioinformatics and artificial intelligence propels the advancement of biotechnology, underpinning sustainable socioeconomic growth, whilst providing potent tools and strategies for researchers and policymakers. Although novel technologies bring opportunities, the potential risks and challenges must be vigilantly monitored. It is anticipated that future research will probe deeper into the application of bioinformatics and artificial intelligence in biotechnology, facilitating sustainable development within this sector.

References

[1] Khalil, A. M. The genome editing revolution. Journal of genetic engineering and biotechnology, 2020, 18(1): 1-16.

[2] Nidhi, S., Anand, U., Oleksak, P., et al. Novel CRISPR–Cas systems: an updated review of the current achievements, applications, and future research perspectives. International journal of molecular sciences, 2021, 22(7): 3327.

[3] Yu, S., Price, M. A., Wang, Y., et al. CRISPR-dCas9 mediated cytosine deaminase base editing in Bacillus subtilis. ACS Synthetic Biology, 2020, 9(7): 1781-9.

[4] Li, T., Yang, Y., Qi, H., et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy, 2023, 8(1): 1-23.

[5] Hough, S. H., Ajetunmobi, A., Brody, L., et al. Desktop genetics. Future Medicine. 2016: 517-21

[6] Khaled, M., Moustafa, A. S., El-Khazragy, N., et al. CRISPR/Cas9 mediated knock-out of VPREB1 gene induces a cytotoxic effect in myeloma cells. PloS one, 2021, 16(1): e0245349.

[7] My, I., Di Pasquale, E. Genetic cardiomyopathies: the lesson learned from hiPSCs. Journal of Clinical Medicine, 2021, 10(5): 1149.

[8] WareJoncas, Z., Campbell, J. M., Mart ńez-G álvez, G., et al. Precision gene editing technology and applications in nephrology. Nature Reviews Nephrology, 2018, 14(11): 663-77.

[9] Rajput, M., Choudhary, K., Kumar, M., et al. RNA interference and CRISPR/Cas gene editing for crop improvement: Paradigm shift towards sustainable agriculture. Plants, 2021, 10(9): 1914.

[10] Petersen, G. E. L., Buntjer, J. B., Hely, F. S., et al. Modeling suggests gene editing combined with vaccination could eliminate a persistent disease in livestock. Proceedings of the National Academy of Sciences, 2022, 119(9): e2107224119.

[11] Qaim, M. Role of new plant breeding technologies for food security and sustainable agricultural development. Applied Economic Perspectives and Policy, 2020, 42(2): 129-50.

[12] Friedrichs, S., Takasu, Y., Kearns, P., et al. Meeting report of the OECD conference on "genome editing: applications in agriculture—implications for health, environment and regulation". Springer. 2019

[13] Grigorian Shamagian, L., Madonna, R., Taylor, D., et al. Perspectives on directions and priorities for future preclinical studies in regenerative medicine. Circulation research, 2019, 124(6): 938-51.

[14] Ewens, M., Farre-Mensa, J. Private or public equity? The evolving entrepreneurial finance landscape. Annual Review of Financial Economics, 2022, 14: 271-93.
[15] Hua, K., Zhang, J., Botella, J. R., et al. Perspectives on the application of genome-editing technologies in crop breeding. Molecular Plant, 2019, 12(8): 1047-59.
[16] Sutherland, W. J., Broad, S., Butchart, S. H., et al. A horizon scan of emerging issues for global conservation in 2019. Trends in ecology & evolution, 2019, 34(1): 83-94.
[17] Smaïl-Tabbone, M., Rance, B. Contributions from the 2019 Literature on Bioinformatics and Translational Informatics. Yearbook of Medical Informatics, 2020, 29(01): 188-92.
[18] Nedelea, A.-M., Mironiuc, M., Huian, M. C., et al. Modeled interdependencies between intellectual capital, circular economy and economic growth in the context of bioeconomy. Amfiteatru Economic, 2018, 20(49): 616-30.
[19] Stalidzans, E., Dace, E. Sustainable metabolic engineering for sustainability optimisation of industrial biotechnology. Computational and Structural Biotechnology Journal, 2021, 19: 4770-6.
[20] KC, M., Lamichhane, A. Advances In Agricultural Biotechnology. Nepal Journal of Biotechnology, 2021, 9(1): 85-92.
[21] Bagabir, S. A., Ibrahim, N. K., Bagabir, H. A., et al. Covid-19 and Artificial Intelligence: Genome sequencing, drug development and vaccine discovery. Journal of Infection and Public Health, 2022, 15(2): 289-96.
[22] Perez-Pinera, P., Ousterout, D. G., Gersbach, C. A. Advances in targeted genome editing. Current opinion in chemical biology, 2012, 16(3-4): 268-77.
[23] Cobb, A. B., Duell, E. B., Haase, K. B., et al. Utilizing mycorrhizal responses to guide selective breeding for agricultural sustainability. Plants, People, Planet, 2021, 3(5): 578-87.
[24] Selvakumar, S. C., Preethi, K. A., Ross, K., et al. CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer. Molecular Cancer, 2022, 21(1): 1-14.
[25] Lu, J., Ding, J., Liu, Z., et al. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment. International Journal of Oncology, 2022, 60(2): 1-23.
[26] Tarim, E. A., Karakuzu, B., Oksuz, C., et al. Microfluidic-based virus detection methods for respiratory diseases. Emergent Materials, 2021, 4: 143-68.
[27] Chiu, C.-F., Chen, W.-C., Ho, L.-H., et al. A method to construct key success factors in the cell therapy industry. Science Progress, 2021, 104(S3): 1-21.
[28] Keen, J. C., Moore, H. M. The genotype-tissue expression (GTEx) project: linking clinical data with molecular analysis to advance personalized medicine. Journal of personalized medicine, 2015, 5(1): 22-9.
[29] Schaly, S., Ghebretatios, M., Prakash, S. Baculoviruses in gene therapy and personalized medicine. Biologics: Targets and Therapy, 2021, 15: 115-32.
[30] Zhou, J., Luan, X., Liu, Y., et al. Strategies and Methods for Improving the Efficiency of CRISPR/Cas9 Gene Editing in Plant Molecular Breeding. Plants, 2023, 12(7): 1-19.
[31] Prins, B. P., Leitsalu, L., Pärna, K., et al. Advances in genomic discovery and implications for personalized prevention and medicine: Estonia as example. Journal of personalized medicine, 2021, 11(5): 1-19.
[32] Phillips, K. A., Trosman, J. R., Kelley, R. K., et al. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health affairs, 2014, 33(7): 1246-53.
[33] Jakka, S., Rossbach, M. An economic perspective on personalized medicine. The HUGO Journal, 2013, 7(1): 1-6.
[34] Koleva-Kolarova, R., Buchanan, J., Vellekoop, H., et al. Financing and reimbursement models for personalised medicine: a systematic review to identify current models and future options. Applied Health Economics and Health Policy, 2022, 20(4): 501-24.
[35] Laferton, J. A., Kube, T., Salzmann, S., et al. Patients' expectations regarding medical treatment: a critical review of concepts and their assessment. Frontiers in psychology, 2017, 8: 1-12.
[36] Faasse, K., Petrie, K. J. The nocebo effect: patient expectations and medication side effects. Postgraduate medical journal, 2013, 89(1055): 540-6.
[37] Quinn, D. M., Earnshaw, V. A. Understanding concealable stigmatized identities: The role of identity in psychological, physical, and behavioral outcomes. Social Issues and Policy Review, 2011, 5(1): 160-90.
[38] Smith, L. E., Webster, R. K., Rubin, G. J. A systematic review of factors associated with side‐effect expectations from medical interventions. Health Expectations, 2020, 23(4): 731-58.
[39] Shedden-Mora, M. C., Pan, Y., Heisig, S. R., et al. Optimizing expectations about endocrine treatment for breast cancer: results of the randomized controlled psy-breast trial. Clinical Psychology in Europe, 2020, 2(1): 1-20.
[40] Kumuthini, J., Mbiyavanga, M., Chimusa, E. R., et al. Minimum information required for a DMET experiment reporting. Pharmacogenomics, 2016, 17(14): 1533-45.
[41] Oliveira, A. F., Pessoa, A. C., Bastos, R. G., et al. Microfluidic tools toward industrial biotechnology. Biotechnology progress, 2016, 32(6): 1372-89.
[42] Abideen, A. S. Constraints in the application of biotechnology to cassava production in Nigeria. International Letters of Natural Sciences, 2013, (4): 26-33.
[43] Jahandideh, F., Bourque, S. L., Wu, J. A comprehensive review on the glucoregulatory properties of food-derived bioactive peptides. Food chemistry: X, 2022, 13: 1-15.
[44] Tomoni, A., Lees, J., Santana, A. G., et al. Pseudokinases: From allosteric regulation of catalytic domains and the formation of macromolecular assemblies to emerging drug targets. Catalysts, 2019, 9(9): 1-17.